Transethosomes for Rheumatoid Arthritis Therapy: A Promising Drug Delivery System

Background: Rheumatoid arthritis (RA) remains a major global health burden affecting approximately 0.5-1% of the adult population. Current disease-modifying antirheumatic drug (DMARD) therapies, including methotrexate and biologic agents, demonstrate limited bioavailability, inadequate synovial tissue penetration, and dose-limiting systemic toxicity, resulting in suboptimal disease control in 30-40% of patients. The synovial-blood barrier restricts drug delivery to affected joints, necessitating higher systemic doses that increase hepatotoxicity, bone marrow suppression, and gastrointestinal complications. Introduction: Transethosomes represent an innovative nanotechnology-based delivery system combining deformable lipid vesicles with edge activators (ethanol, terpenes) to overcome biological barriers. These elastic nanovesicles demonstrate 2-3fold superior deformability compared to conventional liposomes, enabling enhanced tissue penetration and cellular uptake while preferentially targeting inflamed synovial tissue through enhanced permeability and retention (EPR) effect mechanisms. Methodology: This comprehensive review synthesizes preclinical and emerging clinical evidence on transethosomal formulations for RA through systematic analysis of in vitro studies, ex vivo tissue models, in vivo animal models (collagen-induced arthritis, adjuvant-induced arthritis), and early-phase clinical development data. Comparative analysis with alternative delivery systems (liposomes, niosomes, micelles, nanoparticles) and future perspectives on clinical translation were evaluated. Results: Preclinical studies demonstrate that methotrexate-loaded transethosomes achieve 65-75% disease suppression at 0.5-1.0 mg/kg intra-articular dose, compared to 25-35% with free MTX at equivalent doses and 40-50% with conventional liposomes. Transethosomes reduce systemic MTX exposure 4-8 fold (Cmax: 1.5-2.5 μM vs. 8-12 μM for free MTX), dramatically reducing hepatotoxicity risk while enhancing synovial tissue accumulation 10-20 fold. Cellular uptake studies show 3-5 fold higher transethosomal internalization compared to conventional liposomes. Superior intracellular drug bioavailability enables 2-5 fold enhanced anti-inflammatory efficacy. Conclusion: Transethosomes represent a genuine technological advancement addressing fundamental limitations of conventional RA therapeutics. The combination of superior efficacy, dramatically reduced systemic toxicity, and potential for non-invasive administration (topical/transdermal/oral) positions transethosomes as transformative next-generation RA therapy. Realistic clinical availability is anticipated within 4-6 years, with substantial potential to improve outcomes for millions of RA patients globally.